Trimetrexate isethionate
Based on 3 publication(s) in Google Scholar
Trimetrexate (CI-898) isethionate is an antibiotic, also a potent and orally active dihydrofolate reductase (DHFR) inhibitor, reducing the production of DNA and RNA precursors and leading to cell death, with IC50 values of 4.74 nM and 1.35 nM for human DHFR and Toxoplasma gondii DHFR. Trimetrexate isethionate can also inhibit the growth of various cancer cells. Trimetrexate isethionate can be used for researching Pneumocystis carinii pneumonia (PCP) and cancer.
For research use only. We do not sell to patients.
- CAS No.: 82935-04-4
- Formula: C21H29N5O7S
- Molecular Weight:495.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Trimetrexate isethionate
MoreAll Antibiotic Isoforms
MoreAll Parasite Isoforms
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
|
Toxoplasma |
Trimetrexate isethionate (0.1 μM; 18 h) completely inhibits proliferation of toxoplasma in murine macrophages[3].
Trimetrexate isethionate (1 μM) can cross the toxoplasma cell membrane and rapidly reaches high intracellular concentrations (108 pmol/107 cells within 10 min) [3].
Trimetrexate (0.1 mM; 24 h) inhibits cell growth by 50-60% in SNU-C4 and NCI-H630 cell lines[5].
Trimetrexate (1 and 10 mM; 24 h) produces lethality and inhibits DHFR in C4 cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SNU-C4 and NCI-H630
-
Concentration:0.1 mM
-
Incubation Time:24 h
-
Result:Inhibited cell growth by 50-60% in both cell lines.
-
Cell Line:C4 cells
-
Concentration:1 and 10 mM
-
Incubation Time:24 h
-
Result:Produced 42% and 50% lethality at 1 and 10 mM, respectively.
Trimetrexate (0-30 mg/kg; i.v.; once daily for 5days) isethionate shows chronic toxicity in rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Toxoplasma infected female BALB/c mice weighing about 20 g[3]
-
Dosage:180 mg/kg or 30 mg/kg
-
Administration:180 mg/kg per day orally in the drinking water or 30 mg/kg per day i.p.
-
Result:Extended the median survival of the infected mice to 10 d (p.o.) or 19 d (i.p.).
-
Animal Model:Charles River Wistar Crl(WI)BR rats weighing approximately 150 to 200 g[4]
-
Dosage:0, 1, 10, or 30 mg/kg
-
Administration:Intravenous injection, once daily for 5 consecutive days followed by a 23-day recovery period
-
Result:Showed chronic toxicity, the testicular changes persisting during the course of multiple cycles of dosing were not reversible within 21 days, but required an additional 56 days for essentially complete recovery.
Chemical Information
-
CAS No. 82935-04-4
-
Molecular Weight 495.55
-
Formula C21H29N5O7S
-
SMILES
OCCS(=O)(O)=O.NC1=NC(N)=C2C(C)=C(CNC3=CC(OC)=C(OC)C(OC)=C3)C=CC2=N1
-
Synonyms
CI-898 isethionate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
IQGAP3 bridges matrix stiffness with glioma stem cell maintenance and radioresistance by stabilizing SOX2. [Abstract]2026 Jun 6. PMID: 42251046 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Antimicrob Agents Chemother
Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus. [Abstract]2024 Oct 29:e0105124. PMID: 39470195
Purity & Documentation
References
[1]. Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019 Feb 14;62(3):1562-1576. [Content Brief]
[2]. Fulton, B., et al. Trimetrexate. Drugs 49, 563–576 (1995). [Content Brief]
[3]. Allegra CJ, et al. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest. 1987 Feb;79(2):478-82. [Content Brief]
[4]. Dethloff LA, et al. Chronic toxicity of the anticancer agent trimetrexate in rats. Fundam Appl Toxicol. 1992 Jul;19(1):6-14. [Content Brief]
[5]. Grem JL, Voeller DM, Geoffroy F, Horak E, Johnston PG, Allegra CJ. Determinants of trimetrexate lethality in human colon cancer cells. Br J Cancer. 1994 Dec;70(6):1075-84. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz